Abstract:Macrophages play a key role in maintaining tissue homeostasis, regulating immune responses, and promoting tumor progression.1Locati M. Curtale G. Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity.Annu. Rev. Pathol. 2020; 15: 123-147Crossref PubMed Scopus (546) Google Scholar Dysregulation of macrophage polarization between the pro-inflammatory M1 and anti-inflammatory M2 phenotypes worsens inflammation, leading to the development of inflammatory-related diseases. Investigators have developed numerous strategies to regulate the balance of M1/M2 macrophage ratio and cytokine content, which may serve as a practical approach for reverse inflammatory status for various disease treatments. Exploring novel vectors to genetically regulate macrophages in vitro and in vivo is attractive. The targeted gene delivery to macrophages is a crucial challenge for boosting gene therapeutic efficacy. Incorporating ligands such as mannose and transferrin into gene transfer vectors has significantly improved delivery efficiency toward native macrophages.2Ferkol T. Perales J.C. Mularo F. Hanson R.W. Receptor-mediated gene transfer into macrophages.Proc. Natl. Acad. Sci. USA. 1996; 93: 101-105Crossref PubMed Scopus (160) Google Scholar In addition to these ligand-based approaches, various bacterial and protozoan microorganisms have been used to infect macrophages and establish chronic infections, representing a potential powerful method to transfer therapeutic DNA agents to macrophages in vivo.3Mantovani A. Allavena P. Marchesi F. Garlanda C. Macrophages as tools and targets in cancer therapy.Nat. Rev. Drug Discov. 2022; 21: 799-820Crossref PubMed Scopus (70) Google Scholar,4Vaccaro D.E. Symbiosis therapy: the potential of using human protozoa for molecular therapy.Mol. Ther. 2000; 2: 535-538Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar However, utilizing these intracellular microorganisms raises biosafety concerns. To overcome these challenges, in an article recently published in Molecular Therapy - Nucleic Acids, Song et al. developed size-controlled liposomes that encapsulate microRNAs (miR/MT-Lip) to facilitate the M1 to M2 polarization switch and reduce inflammation without deleterious effects on cells.5Park M. Oh H.J. Han J. Hong S.H. Park W. Song H. Liposome-mediated small RNA delivery to convert the macrophage polarity: a novel therapeutic approach to treat inflammatory uterine disease.Mol. Ther. Nucleic Acids. 2022; 30: 663-676Abstract Full Text Full Text PDF PubMed Google Scholar By delivering miR-10a to macrophages, the switch from M1 to M2 macrophages in the uterus suppressed local inflammation, thereby restoring infertility due to uterine inflammation. Compared with other active targeting techniques relying on ligands, such as antibodies or mannose, this size-dependent approach is more feasible in achieving therapeutic goals. The size control is much easier to achieve than the decoration of ligands, which generally require tedious modification processes. Moreover, this approach can reduce biosafety concerns. Overall, this approach shows great promise in boosting macrophage targeting. The reported delivery system, MT-Lip, uses liposomes containing phospholipids and cholesterol as carriers to deliver microRNAs into macrophages. PEI is added to the liposomes to enhance RNA loading capacity and macrophage internalization. The authors also control the size of the liposomes by adjusting the proportion of cholesterol in total lipids. By obtaining larger-sized liposomes (∼1.24 μm), they achieved a higher macrophage-specific internalization rate. The authors tested their delivery system by co-incubating fluorescently labeled microRNA (miRNA) with two different cell lines: HEK293T cells and RAW 264.7 cells. After evaluating cell internalization using fluorescence microscopy and flow cytometry, the authors found that MT-Lip-encapsulated miRNA was specifically internalized by RAW 264.7 cells but not HEK293T cells. In corresponding in vivo experiments, MT-Lip-delivered fluorescent miRNAs had signals only in splenic macrophages, with almost undetectable fluorescent signals in other immune cells such as neutrophils, natural killer (NK) cells, T cells, B cells, dendritic cells (DCs), and peripheral blood mononuclear cells (PBMCs). These findings suggest that MT-Lip can specifically target macrophages, which has great potential for treating macrophage-related diseases. The authors achieved M2 polarization of macrophages at both cellular and in vivo levels using MT-Lip encapsulated with miR-10a (miR-10a/MT-Lip). In RAW 264.7 cells treated with lipopolysaccharide (LPS), miR-10a/MT-Lip converted M1 macrophages into M2 macrophages, as indicated by upregulated expression of related molecular markers. In vivo, the researchers analyzed splenocytes and PBMCs to evaluate macrophage-specific targeting of their miR/MT-Lip in immune cells. They found that miR-10a/MT-Lip specifically targeted macrophages without disturbing other immune cells in the spleen of mice with inflammation induced by LPS. Finally, in a mouse model of Asherman’s syndrome (AS) characterized by sterile inflammation and fibrosis, the therapeutic effects of miR-10a/MT-Lip were evaluated through intravenous injection for several days. The treatment successfully decreased the M1/M2 ratio and increased the number of M2 macrophages without affecting other uterine cell types or immune cells. In addition to miRNAs, long non-coding RNAs (lncRNAs) are a crucial class of non-coding RNAs that have functional significance in various ways, such as influencing chromatin function, modulating stability and translation of cytoplasmic mRNAs, and interfering with signaling pathways through several mechanisms. Recent research has demonstrated that lncRNAs can participate in M1/M2 polarization and possess multifunctional roles in disease progression. For instance, growth-arrest-specific transcript 5 (GAS5) lncRNA overexpression has been observed to inhibit JAK2/STAT3 signaling, thereby promoting M1 polarization.6Chi X. Ding B. Zhang L. Zhang J. Wang J. Zhang W. lncRNA GAS5 promotes M1 macrophage polarization via miR-455-5p/SOCS3 pathway in childhood pneumonia.J. Cell. Physiol. 2019; 234: 13242-13251Crossref PubMed Scopus (49) Google Scholar This phenomenon was recognized in childhood lung inflammation and held significant potential for developing pneumonia-targeting therapeutic strategies. Although Song et al.’s approach is aimed at miRNA delivery, it is suggested that this system could deliver small interfering RNAs (siRNAs) targeting GAS5 lncRNA, and effectively hinder macrophage polarization to M1 by decreasing the amount of lncRNAs and mitigating related inflammatory responses. Moreover, regulating M1/M2 macrophage polarization is applied in various medical scenarios, such as tumor therapy, tissue engineering, and inflammatory diseases. Nanomedicine is developing rapidly in tumor immunotherapy and is expected to break through the bottlenecks and challenges in immunotherapy. Deeply exploiting the role of biomaterials in macrophage action and polarization will significantly accelerate the development of novel macrophage therapies combined with immunomodulatory biomaterials. Applications in different biological scenarios must be accompanied by more relevant basic research. Analysis of cellular or tissue responses to immunomodulatory biomaterials using state-of-the-art high-throughput gene expression profiling can reveal a more complete and more evident interconnection between relevant biochemical signals in tumor immunotherapy, inflammation, and healing processes. Fascinatingly, rapidly developing artificial intelligence (AI) and big data strategies aim to find applications in medical research that combine strategies for cancer nanomedicine and immunotherapy. A shared cloud service platform for analyzing the interaction of immune cells, tissues, and organs can be established and opened in the future. It is worth noting that the phenotypic conversion of macrophages plays a multifaceted role in different diseases or stages of the same disease, as it reflects changes in the body’s immune status. Different macrophage phenotypes can determine the development and outcome of a disease to a considerable extent. Appropriately intervening in the signaling pathways and local microenvironment of macrophage polarization can steer macrophages toward an expected direction for treating diseases. However, M1 macrophages may also exert beneficial effects in some scenarios, such as clearing infections or cancer cells.3Mantovani A. Allavena P. Marchesi F. Garlanda C. Macrophages as tools and targets in cancer therapy.Nat. Rev. Drug Discov. 2022; 21: 799-820Crossref PubMed Scopus (70) Google Scholar,7Alvarez M.M. Liu J.C. Trujillo-de Santiago G. Cha B.H. Vishwakarma A. Ghaemmaghami A.M. Khademhosseini A. Delivery strategies to control inflammatory response: modulating M1-M2 polarization in tissue engineering applications.J. Control. Release. 2016; 240: 349-363Crossref PubMed Scopus (143) Google Scholar Therefore, when using macrophage polarity to treat diseases, it is necessary to consider different diseases and their physiological stages and determine when and how to perform the phenotypic conversion. We are grateful to the National Natural Science Foundation of China (21574136), Guangdong Basic and Applied Basic Research Foundation (2022A1515140073), and the Youth Innovation Promotion Association Program of CAS (2015008). D.W. and J.Z. prepared the original draft, and J.C. reviewed and edited the manuscript. The authors declare no competing interests.

Abstract 2751: ENIGMACTM Discovery Platform Enables Gene to Function Target Validation for Macrophage Therapy

Abstract LB201: ENIGMAC platform enables at-scale CRISPRi screenings for macrophage target discovery

Abstract 6538: Modulation of human macrophage differentiation, phenotype and function in vitro as a strategy to characterize novel tumor microenvironment modulators

Abstract A122: Deciphering macrophage targeting cancer immunotherapies using a novel in vitro assay modelling the tumor microenvironment

Integration of single-cell and bulk transcriptome analyses unravels a macrophage-based gene signature for prognostication and treatment in triple-negative breast cancer

Abstract 5247: Reprogramming tumor microenvironment with intratumor macrophage adoptive cell therapy in melanoma

Abstract 6628: Mapping the spatial and molecular determinants of macrophage heterogeneity in breast cancer

Abstract 5249: Macrophages expressing synthetic cytokine receptors reverse IL10-mediated immunosuppression within solid tumors and promote adaptive immunity

Cellular Heterogeneity of Activated Primary Human Macrophages and Associated Drug-Gene Networks: From Biology to Precision Therapeutics

Abstract PO3-26-08: Genetic modification of tumor associated macrophages using CRISPR lipid nanoparticle platform altered tumor microenvironment and induced cancer cell elimination

Abstract LB040: MACO-355, a unique pan-LILR monoclonal antibody for cancer therapy, re-programs and stimulates immuno-suppressive macrophages in a novel ligand-binding blocking independent manner

Abstract 3092: MICRO-TAG: A novel fluorescence-based real-time cellular target engagement platform for drug discovery

Abstract 5244: SIRPα knockout iPSC-derived macrophages (iMACs) are resistant to CD47-dependent inhibition of phagocytosis and efficiently kill tumor cells in pre-clinical models

Oversized Liposomes Boost Macrophage-Targeted RNA Delivery to Regulate Macrophage Polarity

Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages

Abstract 6868: Exploring myeloid landscapes according to EGFR mutated NSCLC tumor microenvironment

Abstract PO021: Lung cancer cells and cancer-associated fibroblasts drive macrophage polarization in a co-culture model

Tumor-on-a-chip Platform to Interrogate the Role of Macrophages in Tumor Progression

Abstract IA016: Mapping microglia – tumor crosstalk in pediatric brain cancer

Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma